CONVERT-GROUP
Consumers and patients globally have turned to digital platforms to purchase their prescription (Rx), non-prescription (OTC) medication and parapharmacy products with more than 2.7 billion online visits to leading ePharmacies across 96 countries in Q1’21. This represents an astonishing 43% growth rate compared to Q1’20. The details of this global research have been published online at epharmacydata.com .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210701005087/en/
The study highlights the unique opportunity for Consumer Healthcare Retailers and Manufacturers to address the new habits of consumers and patients purchasing their prescription (Rx) and non-prescription (OTC) medicine and parapharmacy products online. Out of the 96 countries having at least 1 online pharmacy, consumers can order their prescription drugs online in 47 countries. The COVID-19 pandemic, wide adoption of electronic prescription , and the modernisation of last mile logistics have worked wonders towards allowing the sale of prescription drugs through eCommerce in the last year, something that was unimaginable 5 years ago in most of the 47 countries. For example, in April 2020 the State Duma of the Russian Federation legalized within days, after years of deliberation, the online sales of prescription and over-the-counter drugs, with the exception of narcotic and psychotropic drugs.
Online Pharmacies are one of the fastest rising eCommerce sectors in the world:
● Amazon invested heavily in the industry with the acquisition of PillPack in 2020.
● JD Health , a unit of JD.com Inc ., increased its revenue, jumping to a +76% year-over-year growth to $1.34 billion, in the first six months of 2020.
● Alibaba -backed Alibaba Health posted a +74% revenue increase over the March to September 2020 period.
● While brick and mortar pharmacy chains such as CVS & Walgreens in the USA surpass 100 million online visits and Boots averages 20 million online visits , pure ecommerce players such as 1mg in India, Consultaremedios in Brazil and Apteka in Russia have been growing extremely fast, with more than 20 million visits per month on average for the last 6 months, disrupting global markets with services such as doctors appointments booking, marketplace capabilities and online consultations.
The research was performed by Convert Group , the leading global ePharmacy Data firm that Consumer Healthcare & FMCG Manufacturers such as Bayer, GSK, J&J, L'Oréal, Nestlé, P&G, Perrigo, Pierre Fabre, Reckitt Benckiser, Roche, Unilever, and others trust for their data-driven strategy and sell-out insights on the eCommerce channel. Traffic data was drawn with permission from Similarweb , the global leading provider of digital market intelligence, for 3.478 Online Pharmacies in 96 Countries across all continents.
Key findings include:
● 47 in 96 countries allow the online ordering of prescription medicine (Rx)
● 88 in 96 countries allow the online ordering of non-prescription medicine (OTC). The only countries prohibiting it are Algeria, Cyprus, Greece, Morocco and Turkey.
● North America was the region with the highest growth, with online visits increasing by +114%. Online visits increased by +80% in South America and +78% in Northern Africa .
● Sweden was the leading country with 18,001 visits to online pharmacies per 1,000 residents , followed by 13,208 visits per 1,000 residents in Bulgaria, 10,418 visits per 1,000 residents in Lithuania, and x 9,739 visits per 1,000 residents in the UK.
● Brazil has the most tier1 online pharmacies (pharmacies with more than 5M visits per average month in Q1’21) with 6 total, followed by Russia with 4, and the U.S. , UK and India with 3 each.
Panayotis Gezerlis , CEO of Convert Group, commented: "During the first lockdown we saw the majority of patients & consumers across countries adopting online purchase habits from ePharmacies with tremendous speed. Many of the newcomers were also supported by ePrescription legislation being adopted across a number of countries, beside the current global eCommerce hype. In some countries more than 20% of Consumer Healthcare revenues are now originating online. We feel that, with the current growth trends, it is likely that by 2035 more than half of the total sales of Rx, OTC and parapharmacy products will be happening online, in the majority of global markets."
The results of the study are now published on the newly-launched epharmacydata.com and will be distributed at the 2021 Global ePharmacy Summit on September 22 - 24, 2021, hosted by Convert Group. epharmacydata.com will be updated monthly to offer the global Consumer Healthcare community insights and data on one of the fastest rising sectors of global eCommerce.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210701005087/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zayed Sustainability Prize Honours Global Pioneers Advancing Progress14.1.2026 02:35:00 CET | Press release
US$5.9M awarded to 11 organisations and high schools from the UAE, Brazil, Canada, Nepal, Switzerland, Uganda and across six sustainability categories From AI-enabled diagnostics to Cooling-as-a-Service, this year’s winners deliver locally adapted innovations that empower millions In 18 years, the Prize has scaled solutions reaching more than 411 million people globally The Zayed Sustainability Prize, the UAE’s pioneering award for innovative solutions to global challenges, today announced the cohort of 2026 winners, celebrating 18 years of empowering communities and driving inclusive, sustainable progress around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113958706/en/ The 2026 winners of the Zayed Sustainability Prize were recognised by the President of the UAE in Abu Dhabi on 13 January 2026 (Photo: AETOSWire) In a ceremony held during Abu Dhabi Sustainability Week (ADSW) and attended by Heads of State, M
Alta Semper Secures USD 57.5 Million from EIB Group and IFC for Growth Fund II to Expand Healthcare Access Across Africa13.1.2026 19:30:00 CET | Press release
Alta Semper Capital LLP (“Alta Semper”), a London-based private equity firm focused on healthcare and consumer investments in high-growth markets, today announced that it has secured USD 57.5 million in commitments to Alta Semper Growth Fund II. These commitments come from a consortium of investors including the European Investment Bank (EIB) Group and the International Finance Corporation (IFC). This landmark partnership was signified earlier today with a momentous signing ceremony held at a Government Ministry in Cairo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113837616/en/ Andrew McDowell (EIB), Cheick Oumar Sylla (IFC), Gelsomina Vigliotti (EIB), Rania Al-Mashat (Minister of Planning, Economic Development and International Cooperation of Egypt), Bassel Rahmy (MSMEDA), Afsane Jetha (CEO, Alta Semper) and Mark Bryson-Richardson MBE (British Ambassador to Egypt) at the signing ceremony in Cairo. (Photo: AETOSWire)
500 Global and Creators HQ Support Creators and Founders Building Startups Collectively Valued at US$130M+13.1.2026 17:00:00 CET | Press release
500 Global, one of the world’s most active Silicon Valley-based venture capital firms1, and Creators HQ, the first content creator hub in the UAE and the Middle East enabling the creator ecosystem globally, announced the Creators Ventures Accelerator program is building and supporting creator-led startups collectively valued at over US$130 million.2 The Creators Ventures Accelerator received over 1,100 applications from content creators and technology startup founders across more than 70 countries. Following a competitive selection process, 21 creators and founders were chosen for the program. This cohort serves a community of 20M+ followers, subscribers, and users across platforms. “Creators represent a growing class of bona fide entrepreneurs, with 50 million creators globally, projected to grow at 10-20% annually over the next 5 years. The first iteration of this industry was built on visibility and virality to monetize. With consumers getting savvier and more discerning, we believe
Nexo Becomes First-Ever Title Partner of the U.S. ATP 500 Dallas Open in Multi-Year Deal13.1.2026 16:30:00 CET | Press release
The agreement builds on Nexo’s long-term approach to partnerships with established global sports institutions. Nexo, the digital assets wealth platform, has been named the U.S. ATP 500 Dallas Open’s first-ever Title Partner under a multi-year agreement beginning in 2026, as the company advances its long-term brand strategy through leading global sports properties. The partnership was unveiled in Dallas alongside the debut of the Nexo Dallas Open brand and the resurfacing of two public tennis courts in North Texas. As one of only two ATP 500 tournaments in the U.S. and the country’s sole indoor ATP Tour championship, the Dallas Open places Nexo among a limited group of ATP 500 title partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113901822/en/ The Nexo Dallas Open “This partnership with Nexo represents a transformative milestone for the Dallas Open,” said Tournament Director Peter Lebedevs. “Securing a title spons
Blue Matter Establishes New Capabilities in Biopharma Research & Development Led by Partner, Tara Austraat-Churik13.1.2026 15:01:00 CET | Press release
Blue Matter is pleased to announce that it has established a practice area dedicated to serving clients in biopharmaceutical Research & Development (R&D). The practice is led by Tara Austraat-Churik, a Partner who joined the firm in September 2025. Tara Austraat-Churik has been serving life science clients for more than 20 years. Her areas of expertise include strategy development and implementation, operating model and organizational design, and process optimization in R&D and Medical Affairs. Prior to joining Blue Matter, she served as Managing Director in R&D, Health, Science, and Wellness at EY. She has a robust background in consulting, which also includes roles at Booz Allen Hamilton, Navitas, WPP, and IBM. She holds a BA and MA from the University of Notre Dame and an MSc in Translational Medicine from the University of Edinburgh. The R&D practice, according to Austraat-Churik, exists to help biopharma companies simplify and accelerate the pathway to market. She adds, “R&D organ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
